Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $32.71 Consensus Target Price from Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $32.7143.

Several equities research analysts have weighed in on the company. TD Cowen began coverage on Avalo Therapeutics in a report on Friday, September 5th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Tuesday, October 14th. Cowen assumed coverage on Avalo Therapeutics in a research note on Friday, September 5th. They issued a “buy” rating for the company. BTIG Research reiterated a “buy” rating and issued a $40.00 price target on shares of Avalo Therapeutics in a report on Monday, September 29th. Finally, HC Wainwright upped their price objective on shares of Avalo Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th.

Avalo Therapeutics Trading Down 2.9%

AVTX stock opened at $18.37 on Thursday. The stock has a market capitalization of $333.05 million, a price-to-earnings ratio of -3.43 and a beta of 0.84. The firm’s 50-day moving average price is $17.64 and its two-hundred day moving average price is $11.85. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). Equities analysts predict that Avalo Therapeutics will post -19.07 EPS for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors have recently bought and sold shares of AVTX. BIT Capital GmbH purchased a new stake in Avalo Therapeutics in the third quarter worth about $25,000. Quadrature Capital Ltd bought a new position in shares of Avalo Therapeutics in the 2nd quarter worth approximately $55,000. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics in the 2nd quarter worth approximately $56,000. ADAR1 Capital Management LLC purchased a new position in shares of Avalo Therapeutics in the 1st quarter valued at approximately $80,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $143,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.